Literature DB >> 21725996

Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice.

Andrew M Miller1, Hua Wang, Adeline Bertola, Ogyi Park, Norio Horiguchi, Sung Hwan Ki, Shi Yin, Fouad Lafdil, Bin Gao.   

Abstract

UNLABELLED: Alcoholic and nonalcoholic steatohepatitis are characterized by fatty liver plus inflammation. It is generally believed that steatosis promotes inflammation, whereas inflammation in turn aggregates steatosis. Thus, we hypothesized the deletion of interleukin (IL)-10, a key anti-inflammatory cytokine, exacerbates liver inflammation, steatosis, and hepatocellular damage in alcoholic and nonalcoholic fatty liver disease models that were achieved via feeding mice with a liquid diet containing 5% ethanol for 4 weeks or a high-fat diet (HFD) for 12 weeks, respectively. IL-10 knockout (IL-10(-/-)) mice and several other strains of genetically modified mice were generated and used. Compared with wild-type mice, IL-10(-/-) mice had greater liver inflammatory response with higher levels of IL-6 and hepatic signal transducer and activator of transcription 3 (STAT3) activation, but less steatosis and hepatocellular damage after alcohol or HFD feeding. An additional deletion of IL-6 or hepatic STAT3 restored steatosis and hepatocellular damage but further enhanced liver inflammatory response in IL-10(-/-) mice. In addition, the hepatic expression of sterol regulatory element-binding protein 1 and key downstream lipogenic proteins and enzymes in fatty acid synthesis were down-regulated in IL-10(-/-) mice. Conversely, IL-10(-/-) mice displayed enhanced levels of phosphorylated adenosine monophosphate-activated protein kinase and its downstream targets including phosphorylated acetyl-coenzyme A carboxylase and carnitine palmitoyltransferase 1 in the liver. Such dysregulations were corrected in IL-10(-/-) IL-6(-/-) or IL-10(-/-) STAT3(Hep-/-) double knockout mice.
CONCLUSION: IL-10(-/-) mice are prone to liver inflammatory response but are resistant to steatosis and hepatocellular damage induced by ethanol or HFD feeding. Resistance to steatosis in these mice is attributable to elevation of inflammation-associated hepatic IL-6/STAT3 activation that subsequently down-regulates lipogenic genes but up-regulates fatty acid oxidation-associated genes in the liver.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725996      PMCID: PMC3197882          DOI: 10.1002/hep.24517

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Hepatoprotective role of interleukin 10 in galactosamine/lipopolysaccharide mouse liver injury.

Authors:  H Louis; O Le Moine; M O Peny; B Gulbis; F Nisol; M Goldman; J Devière
Journal:  Gastroenterology       Date:  1997-03       Impact factor: 22.682

2.  A role for interleukin-10 in alcohol-induced liver sensitization to bacterial lipopolysaccharide.

Authors:  Daniell B Hill; Nympha B D'Souza; Eun Y Lee; Ravshan Burikhanov; Ion V Deaciuc; Willem J S de Villiers
Journal:  Alcohol Clin Exp Res       Date:  2002-01       Impact factor: 3.455

3.  Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS.

Authors:  Feng Hong; Barbara Jaruga; Won Ho Kim; Svetlana Radaeva; Osama N El-Assal; Zhigang Tian; Van-Anh Nguyen; Bin Gao
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease.

Authors:  J Grove; A K Daly; M F Bassendine; E Gilvarry; C P Day
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 5.  IL-6 in autoimmune disease and chronic inflammatory proliferative disease.

Authors:  Katsuhiko Ishihara; Toshio Hirano
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

6.  Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse.

Authors:  Kohjiro Ueki; Tatsuya Kondo; Yu-Hua Tseng; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

7.  Increased plasma interleukin-8 concentrations in alcoholic hepatitis.

Authors:  D B Hill; L S Marsano; C J McClain
Journal:  Hepatology       Date:  1993-09       Impact factor: 17.425

8.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway.

Authors:  Ariel E Feldstein; Nathan W Werneburg; Ali Canbay; Maria Eugenia Guicciardi; Steven F Bronk; Robert Rydzewski; Laurence J Burgart; Gregory J Gores
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo.

Authors:  Hiroshi Inoue; Wataru Ogawa; Michitaka Ozaki; Sanae Haga; Michihiro Matsumoto; Kensuke Furukawa; Naoko Hashimoto; Yoshiaki Kido; Toshiyuki Mori; Hiroshi Sakaue; Kiyoshi Teshigawara; Shiyu Jin; Haruhisa Iguchi; Ryuji Hiramatsu; Derek LeRoith; Kiyoshi Takeda; Shizuo Akira; Masato Kasuga
Journal:  Nat Med       Date:  2004-01-11       Impact factor: 53.440

Review 10.  Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target.

Authors:  Hua Wang; Fouad Lafdil; Xiaoni Kong; Bin Gao
Journal:  Int J Biol Sci       Date:  2011-04-27       Impact factor: 6.580

View more
  53 in total

1.  Restoration of Wnt/β-catenin signaling attenuates alcoholic liver disease progression in a rat model.

Authors:  Chiung-Kuei Huang; Tunan Yu; Suzanne M de la Monte; Jack R Wands; Zoltan Derdak; Miran Kim
Journal:  J Hepatol       Date:  2015-02-24       Impact factor: 25.083

2.  Dietary saturated fatty acids reduce hepatic lipid accumulation but induce fibrotic change in alcohol-fed rats.

Authors:  Ya-Ling Chen; Hsiang-Chi Peng; Xiang-Dong Wang; Suh-Ching Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

Review 3.  Immune Cells Gate White Adipose Tissue Expansion.

Authors:  Aaron R Cox; Natasha Chernis; Peter M Masschelin; Sean M Hartig
Journal:  Endocrinology       Date:  2019-07-01       Impact factor: 4.736

Review 4.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

5.  Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis.

Authors:  Selma Masri; Thales Papagiannakopoulos; Kenichiro Kinouchi; Yu Liu; Marlene Cervantes; Pierre Baldi; Tyler Jacks; Paolo Sassone-Corsi
Journal:  Cell       Date:  2016-05-05       Impact factor: 41.582

Review 6.  Alcoholic liver disease: pathogenesis and new therapeutic targets.

Authors:  Bin Gao; Ramon Bataller
Journal:  Gastroenterology       Date:  2011-09-12       Impact factor: 22.682

7.  Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice.

Authors:  Xiaobing Tan; Xiuhua Sun; Qiong Li; Yantao Zhao; Wei Zhong; Xinguo Sun; Wei Jia; Craig J McClain; Zhanxiang Zhou
Journal:  Am J Pathol       Date:  2012-07-27       Impact factor: 4.307

8.  Polychlorinated biphenyls disrupt hepatic epidermal growth factor receptor signaling.

Authors:  Josiah E Hardesty; Banrida Wahlang; K Cameron Falkner; Heather B Clair; Barbara J Clark; Brian P Ceresa; Russell A Prough; Matthew C Cave
Journal:  Xenobiotica       Date:  2017-06-21       Impact factor: 1.908

Review 9.  Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Daniele Balasus; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

10.  Overexpression of variant PNPLA3 gene at I148M position causes malignant transformation of hepatocytes via IL-6-JAK2/STAT3 pathway in low dose free fatty acid exposure: a laboratory investigation in vitro and in vivo.

Authors:  Zhengtao Liu; Tianchi Chen; Xiaoxiao Lu; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.